Dianthus Therapeutics (DNTH) AI Stock Analysis

• Market Cap: $782.18M
• Dividend Yield: N/A
• Average Volume (3M): 349.08K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.10
• Revenue Growth: 17.87%
• EPS Growth: 41.27%
• Country: US
• Employees: 78
• Sector: Healthcare
• Sector Strength: 48
• Industry: Biotechnology
• EPS (TTM): -0.88
• Shares Outstanding: 32,188,347
• 10 Day Avg. Volume: 380,098
• 30 Day Avg. Volume: 349,080
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.53
• Enterprise Value/Revenue: 84.74
• Enterprise Value/Gross Profit: 86.50
• Enterprise Value/Ebitda: -3.17
• 1Y Price Target: $53.29
• Price Target Upside: 127.64% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 10

• Rating: 48 Neutral
• Price Target: $20.50 ▼(-12.43% Downside)

The overall stock score for Dianthus Therapeutics is primarily impacted by its financial performance, which is concerning due to declining revenues and substantial losses. Technical analysis provides some positive signals with short-term bullish momentum, but the valuation remains unattractive due to negative profitability. The absence of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Analyst Rating

Analyst maintains a Buy rating for DNTH with a 12-month price target of $40.00 per share based on a risk-adjusted net present value analysis.

Efficacy of DNTH103

DNTH103's mechanism of action and extended dosing interval is seen as a competitive advantage compared to other treatments.

Financial Stability

Dianthus had approximately $309.1M in cash, cash equivalents, and investments, which is believed to be sufficient to fund planned operations into 2H27, providing a solid financial foundation.

Negative Factors

Efficacy Concerns

Should DNTH103 fall short in efficacy, there is a potential downside risk to the stock price.

Financial Performance

The company reported license revenue for 2Q25 significantly below consensus estimates, which could raise concerns about short-term financial performance.

Market Competition

With recent FcRn antagonist approvals, gMG is an increasingly competitive space.

Dianthus Therapeutics Business Overview & Revenue Model

Company Description

Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.

How the Company Makes Money

Dianthus Therapeutics primarily generates revenue through the development and commercialization of its therapeutic products. The company engages in partnerships and collaborations with larger pharmaceutical firms to co-develop its drug candidates, which can provide upfront licensing fees, milestone payments, and royalties on sales. Additionally, Dianthus may receive funding through government grants or investments from venture capital firms, particularly for its early-stage research and development efforts. Its revenue model is heavily reliant on successful clinical trials and the subsequent approval of its therapies by regulatory agencies, which can lead to significant market opportunities.

Dianthus Therapeutics Financial Statement Overview

Summary

Dianthus Therapeutics shows significant revenue growth but remains unprofitable with negative EBIT and net income. The company has a strong equity position and low debt, yet faces cash flow challenges, relying heavily on external financing.

Income Statement

Dianthus Therapeutics shows significant revenue growth from 2023 to 2024, growing from $2.83 million to $6.24 million. However, the company remains unprofitable, with negative EBIT and net income, resulting in poor profit margins. The gross profit margin is strong at 100%, but this is offset by high operating losses.

Balance Sheet

The company has a strong equity position with a high equity ratio, reflecting solid shareholder backing. The debt-to-equity ratio is low, indicating prudent leverage, but the negative stockholders' equity in prior years highlights potential financial instability.

Cash Flow

Free cash flow remains negative, and operating cash flow is insufficient to cover net income losses. The company relies heavily on financing activities for cash inflow, which could be a risk if external funding becomes less available.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.85M	6.24M	2.83M	6.42M	1.48M	0.00
Gross Profit	4.75M	6.24M	2.83M	6.27M	-544.00K	-1.98M
EBITDA	-129.59M	-101.45M	-47.82M	-29.56M	-69.12M	-72.96M
Net Income	-114.75M	-84.97M	-43.55M	-28.48M	-13.11M	-74.94M
Balance Sheet
Total Assets	326.08M	374.01M	179.41M	83.11M	9.45M	161.62M
Cash, Cash Equivalents and Short-Term Investments	257.39M	275.24M	173.72M	75.49M	176.93M	148.84M
Total Debt	1.33M	1.49M	585.00K	788.00K	0.00	0.00
Total Liabilities	23.00M	21.53M	10.54M	127.48M	26.70M	17.71M
Stockholders Equity	303.08M	352.48M	168.87M	-44.37M	172.67M	143.91M
Cash Flow
Free Cash Flow	-100.36M	-78.28M	-36.97M	-29.21M	-9.94M	-64.42M
Operating Cash Flow	-100.23M	-78.18M	-36.86M	-29.07M	-9.90M	-64.02M
Investing Cash Flow	-241.23M	-286.81M	20.25M	-59.82M	43.43M	-10.63M
Financing Cash Flow	40.70M	255.62M	133.57M	96.68M	89.60M	67.74M

Dianthus Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 23.41
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DNTH, the sentiment is Positive. The current price of 23.41 is above the 20-day moving average (MA) of 21.18, above the 50-day MA of 20.04, and above the 200-day MA of 21.21, indicating a bullish trend. The MACD of 0.89 indicates Negative momentum. The RSI at 62.72 is Neutral, neither overbought nor oversold. The STOCH value of 81.55 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DNTH.

Dianthus Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PHAR	67 Neutral	$934.06M	―	-3.40%	―	22.68%	42.45%
TRVI	55 Neutral	$919.42M	―	-35.74%	―	―	-8.46%
Sector *	51 Neutral	$7.78B	-0.06	-40.08%	2.29%	21.32%	-1.82%
DNTH	48 Neutral	$782.18M	―	-34.71%	―	17.87%	41.27%
IMNM	48 Neutral	$896.56M	―	-81.20%	―	16.74%	59.89%
KALV	45 Neutral	$669.88M	―	-121.50%	―	―	-10.46%
ANAB	40 Underperform	$562.74M	―	-343.83%	―	304.17%	29.37%

Dianthus Therapeutics Corporate Events

Dianthus Therapeutics Announces Board Changes and Elections

On May 22, 2025, Dianthus Therapeutics, Inc. announced the resignation of Leon O. Moulder, Jr. from its Board of Directors, with Simon Read, Ph.D., appointed as a new Class III director. Dr. Read will also join the Science and Technology Committee and the Nominating and Corporate Governance Committee, receiving compensation in line with the company’s Non-Employee Director Compensation Policy. The company also held its Annual Meeting of Stockholders on the same day, where Marino Garcia and Paula Soteropoulos were elected as Class I directors. Additionally, stockholders approved executive compensation and ratified Deloitte & Touche, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.